Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc (SNN), a global leader in medical technology, provides innovative solutions in orthopedic reconstruction, sports medicine, and advanced wound care. This dedicated news hub offers investors and healthcare professionals timely access to SNN's official announcements and market-moving developments.
Track critical updates including quarterly earnings, product approvals, and strategic partnerships that shape the future of surgical technologies. Our curated feed ensures you never miss regulatory milestones, clinical trial results, or executive leadership changes impacting SNN's global operations.
Bookmark this page for streamlined access to verified information directly affecting SNN's market position. Regular updates provide insights into how the company addresses healthcare challenges through robotics, digital surgery platforms, and patient-centric device innovations.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a three-year distribution agreement with Smith+Nephew for its negative pressure wound therapy (NPWT) system. InfuSystem will offer Smith+Nephew's advanced RENASYS◊ EDGE NPWT system, a lightweight and compact option for home-based care of chronic wounds.
The partnership leverages InfuSystem's Patient Services platform and network of over 800 in-network health insurance providers, covering 96% of the U.S. population. This collaboration aims to increase patient access to the RENASYS EDGE technology and create new revenue opportunities for both companies.
InfuSystem's CEO, Richard DiIorio, emphasized the company's ability to provide customized solutions and high-value services around partners' products, making them an attractive secondary distribution partner for Smith+Nephew's NPWT system.
Smith+Nephew (LSE:SN, NYSE:SNN) has announced an exclusive digital and advanced analytics collaboration with Healthcare Outcomes Performance Company (HOPCo) to enhance solutions for Ambulatory Surgery Center (ASC) customers, physicians, and patients. The partnership integrates HOPCo's AI-powered myrecovery platform and Vitals platform with Smith+Nephew's CORI Surgical System.
This collaboration aims to provide comprehensive technology for all musculoskeletal procedures in ASCs, offering patient engagement tools, remote care management, and critical quality outcome metrics. The integration will enhance analytics for personalized surgical planning, intra-operative decision-making, and patient-reported outcomes tracking, potentially improving patient outcomes and reducing costs in value-based care settings.
Smith+Nephew (NYSE:SNN) has received 510(k) clearance for its new CATALYSTEM Primary Hip System from the FDA. This system is designed to meet the evolving demands of primary hip surgery, including the increased adoption of anterior approach procedures and the expanding role of Ambulatory Surgery Centers (ASCs).
Key features of the CATALYSTEM system include:
- A triple-taper stem design with uniform proximal loading
- Reduced distal stem geometry and shorter lengths
- Proprietary ACCUBROACH Technology for reproducibility between broach and implant
- Compatibility with the CORI Surgical System
The system aims to provide precision fit, confidence in stem seating, and surgical efficiencies, making it suitable for diverse patient anatomies and various surgical approaches.
Smith+Nephew has launched the Orthopaedics for All initiative, creating a global advisory board to promote diversity, equity, and inclusion in orthopaedic surgery. The initiative aims to address the significant gender disparity in the field, where only 15% of orthopaedic residents and 7.4% of practicing surgeons in the U.S. are women. The board comprises around 20 leading female surgeons with a minimum of two years of post-fellowship experience. Smith+Nephew's initiative also includes partnerships, like with the Perry Initiative, to inspire young women to pursue careers in orthopaedics.
Smith+Nephew (SNN), a global leader in medical technology, has announced its sponsorship of tennis players at Wimbledon 2024, aiming to spotlight its advanced Sports Medicine solutions. The company offers innovative solutions for common tennis injuries like rotator cuff and meniscus tears. Its REGENETEN Bioinductive Implant for rotator cuff repair has been used in over 100,000 procedures globally, showing significant clinical success. The FAST-FIX Family of meniscal repair solutions boasts a 30-year track record, aiding hundreds of thousands of patients with an 88% success rate in all-inside repairs. Smith+Nephew's sponsorship aligns with its mission to help individuals recover from injuries and return to their favorite activities.
Smith+Nephew announced the launch of CORIOGRAPH Pre-Operative Planning and Modeling Services, enhancing its CORI Surgical System for knee arthroplasty procedures. This innovation aims to provide personalized solutions for surgeons and patients, integrating both image-based and image-free registration options. Dr. Steven Haas, an orthopaedic surgeon, recently completed the first procedures using these services, highlighting their potential to improve surgical efficiency and outcomes. The CORI Surgical System is built on over 15 years of expertise and includes tools like the CORI Digital Tensioner and updated RI.KNEE ROBOTICS 3.0 software.